Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

Recurrent GBM safety

Optune patients experienced fewer systemic AEs vs
chemotherapy1

Incidence of grade 2-4 AEs occurring in ≥5%
of patients2
Optune
(n=116)
%
Chemotherapy
(n=91)
%
Hematologic 3 17
Leukopenia 0 5
Thrombocytopenia 1* 7
Gastrointestinal disorders 4 17
Diarrhea 0 6
Nausea/vomiting 2 7
General Deterioration and Malaise 5 6
Infections 4 8
Metabolism and Nutrition Disorders 4 6
Musculoskeletal Disorders 2 5
Nervous system disorders 30 28
Convulsion 7 5
Headache 8 6
Psychiatric disorders 5 4
*Thrombocytopenia from prior chemotherapy, normalized subsequently.
  • The most common (≥10%) AEs seen with Optune monotherapy were medical device site reaction and headache3

  • The following AEs were considered related to Optune: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer4

    • In EF-11, 16% of patients experienced a grade 1/2 medical device reaction2

  • Mild-to-moderate skin irritation, the most common device-related side effect with Optune, was easily manageable, reversible, and did not result in treatment discontinuation1

Improved safety vs chemotherapy1

  • Significantly fewer of the systemic AEs associated with chemotherapy, including gastrointestinal side effects, hematological side effects, and infections, were observed with Optune



AE, adverse event; GBM, glioblastoma.

References: 1. Optune Instructions For Use. Novocure 2016. 2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2­1­9­2­-­2­2­0­2. 3. Novocure Data on File OPT-109. 4. Novocure Data on File OPT-110.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).